<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Alternate Name</th>
        <th class="naaccr-summary-header naaccr-borders">Item#</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">490</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">SEER/CoC</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">562-562</td>
    </tr>
</table>

<br/><b>Description</b><br/>
Code for the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history.

<br/><br/><b>Rationale</b><br/>
Diagnostic confirmation is useful to calculate rates based on microscopically confirmed cancers. Full incidence calculations must also include tumors that are only confirmed clinically. The percentage of tumors that not micropscopically confirmed is an indication of whether case finding is including sources outside of pathology reports.

<br/><br/><b>
  Codes 
</b><br/>
<table class="naaccr-codes-table">
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">1</td>
        <td class="naaccr-codes-cell">Positive histology</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">2</td>
        <td class="naaccr-codes-cell">Positive cytology</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">3</td>
        <td class="naaccr-codes-cell">Positive histology PLUS - positive immunophenotyping AND/OR positive genetic studies (Used only for hematopoietic and lymphoid neoplasms M-9590/3-9992/3)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">4</td>
        <td class="naaccr-codes-cell">Positive microscopic confirmation, method not specified</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">5</td>
        <td class="naaccr-codes-cell">Positive laboratory test/marker study</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">6</td>
        <td class="naaccr-codes-cell">Direct visualization without microscopic confirmation</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">7</td>
        <td class="naaccr-codes-cell">Radiography and/or other imaging techniques without microscopic confirmation</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">8</td>
        <td class="naaccr-codes-cell">Clinical diagnosis only (other than 5, 6, or 7)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">9</td>
        <td class="naaccr-codes-cell">Unknown whether or not microscopically confirmed; death certificate only</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap"></td>
        <td class="naaccr-codes-cell"> </td>
    </tr>
</table>
<br/>
  <em>Note:</em> Code 3 (used only for hematopoietic and lymphoid neoplasms M-9590/3-9992/3) was adopted for use effective with 2010 diagnoses.
<br/>
